Hodges N G, Brewis R A, Howell J B
Thorax. 1971 Nov;26(6):734-9. doi: 10.1136/thx.26.6.734.
Previous studies of immunosuppressive therapy in asthma have been uncontrolled and conflicting in their results. Two double-blind controlled cross-over trials using two dosage levels of azathioprine (2 mg/kg and 5 mg/kg for three and four weeks respectively) in a total of 20 patients with chronic severe asthma are described. Both objective and subjective assessments by independent observers indicated no significant change in the groups as a whole. However, in four patients, an improvement was attributed to azathioprine therapy. Two patients in whom sputum production was copious showed marked clinical improvement and reduced sputum volume. In four patients, exacerbations of asthma occurred within two weeks of starting azathioprine and a causal relationship was suspected. No serious depression of circulating white blood cells occurred in any patient.
先前关于哮喘免疫抑制治疗的研究缺乏对照，结果相互矛盾。本文描述了两项双盲对照交叉试验，共纳入20例慢性重度哮喘患者，分别使用两种剂量的硫唑嘌呤（2mg/kg和5mg/kg，分别用药3周和4周）。独立观察者进行的客观和主观评估均表明，总体上两组无显著变化。然而，有4例患者的病情改善归因于硫唑嘌呤治疗。2例痰液大量分泌的患者临床症状明显改善，痰液量减少。4例患者在开始使用硫唑嘌呤后两周内哮喘发作，怀疑存在因果关系。所有患者均未出现循环白细胞严重减少的情况。
